Close Menu

Crohn's disease

Analyzing genome sequences from dozens of cases and controls, researchers saw an IBD-associated jump in somatic mutations in colonic crypt samples.

Based in Boston with operations in Ireland and Iceland, the reorganized company is supporting COVID-19 testing and population genomics as it sheds its China division.

The company will apply its single-cell RNA-seq analytics technology to three distinct cohorts in pursuit of new drug targets for inflammatory bowel disease. 

The multi-omics translational software developer is helping the Crohn's & Colitis Foundation validate its research into biomarkers that can predict complications requiring surgery.

The test is designed to analyze the expression of 17 genes in order to differentiate mild and aggressive forms of Crohn's disease and ulcerative colitis.

The study will recruit up to 200 patients with active Crohn's disease or ulcerative colitis and sort them into high- and low-risk cohorts using the PredictSure IBD test. 

The project is part of the Human Cell Atlas, an international effort to build reference maps of all human cell types using single-cell analysis.

Under the deal, KSL will commercialize and facilitate orders of the PredictSURE IBD test throughout North America and will also process all samples through its laboratory, KSL Diagnostics.

Under the expanded deal, PredictImmune will have first right of refusal on technologies for predicting disease outcome for systemic lupus erythematosus.

Addenbrooke' Hospital will manage and facilitate the fulfillment orders of the firm's PredictSure IBD orders, as well as receive and process all samples.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.